1-9 of 9
Xiangao Huang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2300: CDK4/6 inhibition triggers dissociation of MEIS2 from CRL4CRBN E3 ligase to induce interferon response and reprogram myeloma for IMiD vulnerability

Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Zhengming Chen, Anna Schinzel, Scott A. Ely, Adriana Rossi, Morton Coleman, Joseph M. Lane, William C. Hahn, Tomer M. Mark, Ruben Niesvizky, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2300.
https://doi.org/10.1158/1538-7445.AM2018-2300
Published: 01 July 2018
View articletitled, Abstract 2300: CDK4/6 inhibition triggers dissociation of MEIS2 from CRL4CRBN E3 ligase to induce interferon response and reprogram myeloma for IMiD vulnerability
Journal Articles

Abstract 1523: Repression of IRF4 and CYTIP unleashes anti-tumor interferon response in CDK4 inhibitor therapy in mantle cell lymphoma

Maurizio Di Liberto, Peter Martin, Xiangao Huang, Priyanka Vijay, David Chiron, Scott Ely, Christopher Mason, Olivier Elemento, John Leonard, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1523.
https://doi.org/10.1158/1538-7445.AM2018-1523
Published: 01 July 2018
View articletitled, Abstract 1523: Repression of IRF4 and CYTIP unleashes anti-tumor interferon response in CDK4 inhibitor therapy in mantle cell lymphoma
Journal Articles

Abstract 3099: Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor

Priyanka Vijay, Pedro Blecua, Maurizio Di Liberto, David Chiron, Xiangao Huang, Olivier Elemento, Peter Martin, John P. Leonard, Christopher E. Mason, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3099.
https://doi.org/10.1158/1538-7445.AM2015-3099
Published: 01 August 2015
View articletitled, Abstract 3099: Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor
Journal Articles

Abstract 3095: Longitudinal integrative whole transcriptome and exome sequencing identifies genes that reprogram lymphoma cells for clinical response to CDK4/6 inhibition in combination therapy

Maurizio Di Liberto, Peter Martin, David Chiron, Priyanka Vijay, Xiangao Huang, Pedro Blecua, Scott Ely, Olivier Elemento, John P. Leonard, Christopher E. Mason, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3095.
https://doi.org/10.1158/1538-7445.AM2015-3095
Published: 01 August 2015
View articletitled, Abstract 3095: Longitudinal integrative whole transcriptome and exome sequencing identifies genes that reprogram lymphoma cells for clinical response to CDK4/6 inhibition in combination therapy
Journal Articles

Abstract 4031: CDK4/6 inhibition amplifies IMiD killing of myeloma cells by accelerating CRL4CRBN-dependent degradation of IKZF1 and IKZF3 in opposition to MEIS2

Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Tomer M. Mark, Zhengming Chen, Adriana Rossi, Anna C. Schinzel, William C. Hahn, Mohamad A. Hussein, Rubin Niesvizky, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4031.
https://doi.org/10.1158/1538-7445.AM2015-4031
Published: 01 August 2015
View articletitled, Abstract 4031: CDK4/6 inhibition amplifies IMiD killing of myeloma cells by accelerating CRL4CRBN-dependent degradation of IKZF1 and IKZF3 in opposition to MEIS2
Journal Articles

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity

Chenyi Yang, Cynthia A. Boyson, Maurizio Di Liberto, Xiangao Huang, Jeffrey Hannah, David C. Dorn, Malcolm A.S. Moore, Selina Chen-Kiang, Pengbo Zhou
Journal: Cancer Research
Cancer Res (2015) 75 (9): 1838–1845.
https://doi.org/10.1158/0008-5472.CAN-14-2486
Published: 30 April 2015
View articletitled, CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity
Open the PDF for CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity in another window
Includes: Supplementary data
Journal Articles

Abstract 3424: Induction of prolonged early G1-arrest by CDK4/CDK6 inhibition reprograms cycling lymphoma cells for enhanced and sustained inhibition of PI3Kδ/AKT.

David Chiron, Peter Martin, Maurizio Di Liberto, Xiangao Huang, Scott A. Ely, Brian J. Lannutti, John P. Leonard, Christopher E. Mason, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3424.
https://doi.org/10.1158/1538-7445.AM2013-3424
Published: 15 April 2013
View articletitled, Abstract 3424: Induction of prolonged early G1-arrest by CDK4/CDK6 inhibition reprograms cycling lymphoma cells for enhanced and sustained inhibition of PI3Kδ/AKT.
Journal Articles

Abstract 3887: Reversible inhibition of CDK4/CDK6 sensitizes hematological tumor cells for cytotoxic killing by inducing sequential G1 arrest and synchronous S phase entry that enhances the intrinsic apoptosis pathway

Phoebe Joy Ho, Xiangao Huang, Scott Ely, Amy Chadburn, Peter Martin, Malcolm A.S Moore, John Leonard, Ruben Niesvizky, Maurizio Di Liberto, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3887.
https://doi.org/10.1158/1538-7445.AM10-3887
Published: 15 April 2010
View articletitled, Abstract 3887: Reversible inhibition of CDK4/CDK6 sensitizes hematological tumor cells for cytotoxic killing by inducing sequential G1 arrest and synchronous S phase entry that enhances the intrinsic apoptosis pathway
Journal Articles

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

Eline Menu, Josefina Garcia, Xiangao Huang, Maurizio Di Liberto, Peter L. Toogood, Isan Chen, Karin Vanderkerken, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2008) 68 (14): 5519–5523.
https://doi.org/10.1158/0008-5472.CAN-07-6404
Published: 15 July 2008
View articletitled, A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Open the PDF for A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model in another window